-- Humanwell Healthcare (SHA:600079) unit obtained China's regulatory approval to begin clinical trials for RFUS-188 to treat acute pain, according to a Thursday filing with the Shanghai bourse.
The drug targets peripheral kappa opioid receptors without crossing the blood-brain barrier, potentially eliminating the addiction, respiratory depression and other severe side effects of traditional opioids
Shares of the pharmaceutical company declined 1% in recent trade.
Saudi Arabia's business confidence index stood at 54.5 points in April, up from 52.1 points in March, data from the General Authority for Statistics showed Thursday.The monthly change in confidence was 4.6% higher, compared with a 14.2% decrease earlier.The statistics agency noted that the reading reflected sustained optimism in the business sector, underpinned by expectations of continued growth in various segments and confidence in the stability of economic activity.
Germany's monthly factory orders gained 5% in March, following a revised 1.4% increase in February, according to preliminary data from the country's Federal Statistical Office published Thursday.Analysts expected a 1% rise for the month.On a yearly basis, new orders in manufacturing were up 6.3%, against the 3.5% jump earlier.
Jointown Pharmaceutical (SHA:600998) unit Beijing Jingfeng Pharmaceutical Shandong passed a good manufacturing practices (GMP) compliance inspection by the Shandong Medical Products Administration for its tablet production lines.The inspection covered Workshop 801, which produces metformin hydrochloride enteric-coated tablets for type 2 diabetes and isosorbide dinitrate tablets for coronary heart disease and angina, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.